Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Braxia Scientific Stock News

BRAXFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.00090

0.000.00%

At close: -

$0.00100

0.0001011.11%

After Hours: Mar 18, 9:29 AM EDT

Braxia Scientific (BRAXF) Forecast

News

Earnings Braxia Scientific (BRAXF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Braxia Scientific Stock News | OTC:BRAXF | Benzinga

Get the latest news on Braxia Scientific stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Braxia Scientific performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, August 13, 2024

I Saw Trillions Of Atoms In My Hand Vibrating At A Certain Frequency, Says Zappy Zapolin Describing His First Psychedelics Experience
Nina Zdinjak

Saturday, March 02, 2024

Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
Lara Goldstein

Thursday, February 29, 2024

Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Lara Goldstein

Monday, December 11, 2023

Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
Lara Goldstein

Monday, December 04, 2023

Braxia Scientific's Q2 2024: Cash Burn Over But Income Low, What's Next For Psychedelics Company?
Lara Goldstein

Tuesday, September 05, 2023

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Lara Goldstein

Thursday, August 31, 2023

Braxia Scientific Faces Challenges In Accessing Public Market Capital, Reports Q1 Loss
Lara Goldstein

Tuesday, June 13, 2023

Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
Lara Goldstein

Friday, June 09, 2023

BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
Lara Goldstein

Monday, March 20, 2023

Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Lara Goldstein

Thursday, March 16, 2023

Major Ketamine Clinics Chain Decides Not To Pursue Acquisition Deal
Lara Goldstein

Tuesday, March 07, 2023

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Lara Goldstein

Thursday, March 02, 2023

Braxia Scientific's Q3 2023 Finances, Update On Upcoming Acquisition With Irwin Naturals
Lara Goldstein

Tuesday, February 21, 2023

Irwin Naturals Acquires Ketamine Clinic In Kentucky Adding $3M In Projected EBITDA
Vuk Zdinjak

Friday, January 27, 2023

Irwin Naturals Signs LOI To Acquire Braxia Scientific Expanding Its Network Of Mental Health Clinics
Vuk Zdinjak

Tuesday, January 10, 2023

6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Lara Goldstein

Tuesday, December 06, 2022

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Lara Goldstein

Friday, December 02, 2022

Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY
Joana Scopel

Friday, October 07, 2022

Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Lara Goldstein

Wednesday, October 05, 2022

Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
Lara Goldstein

Tuesday, September 13, 2022

Great Psychedelics And Business Events Are Coming In Q4: Check Them Out Here
Lara Goldstein

Tuesday, August 30, 2022

4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
Lara Goldstein

Wednesday, August 03, 2022

Telehealth Market News: Braxia Scientific Enters Industry By Acquiring Ketamine Treatment Platform In Florida
Lara Goldstein

Monday, August 01, 2022

Braxia Scientific Fiscal 2022 Revenue Grows 47.5% YoY, What About Net Loss?
Vuk Zdinjak

Thursday, June 16, 2022

Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments
Lara Goldstein

Wednesday, June 15, 2022

Braxia Opens New Clinic in Ontario, Facilitating Further Access To Ketamine And Psilocybin Treatments
Lara Goldstein

Thursday, June 02, 2022

These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
Natan Ponieman

Monday, October 18, 2021

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman

Wednesday, October 13, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman

Monday, October 04, 2021

Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
Natan Ponieman

Thursday, September 30, 2021

New Study Suggests Ketamine Could Work Better Without Additional Antidepressants
Natan Ponieman

Monday, August 30, 2021

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Natan Ponieman

Friday, August 27, 2021

Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression
Natan Ponieman

Monday, August 02, 2021

Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
Natan Ponieman

Wednesday, July 28, 2021

Braxia Scientific Leadership Receives Funding From Canadian Government To Study Ketamine Therapy
Natan Ponieman

Monday, July 26, 2021

Psyched: Cybin And Field Trip Head To Wall Street, AOC Pushes For Federal Psychedelics Research, Off-Label Ketamine Covered By Insurance In Canada
Natan Ponieman

Thursday, July 22, 2021

Canadian Insurance Provider To Cover Off-Label Use Of Ketamine For Treating Depression
Natan Ponieman

Friday, July 02, 2021

Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Natan Ponieman

Monday, June 21, 2021

Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Natan Ponieman

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved